Stock report · Delisted · Nasdaq
Renovaro Biosciences Inc (RENB)
1.27USD Delisted Final close · Sep 29, 2025
RENB no longer trades. Renovaro Biosciences was delisted from the Nasdaq in September 2025.
All prices on this page are historical. The last trade was on September 29, 2025, at $1.27.
RENB stock price history
Final trading statistics
- Final close
- $1.27
- Final trading day
- Sep 29, 2025
- Market cap at delisting
- $29.35M
- Shares outstanding
- 23.18M
- Final 52-week range
- $0.13 – $2.10
- Avg. volume (final 3 mo.)
- 193,761
- All-time high
- $125.50 · Nov 2021
- All-time low
- $1.27 · Sep 2025
- Return since IPO
- -97.9%
- Beta
- 0.53
- Book value / share
- −$1.20
- Price / book
- -1.05
About Renovaro Biosciences Inc
Renovaro Biosciences was a pre-clinical biotechnology company developing treatments for cancer and HIV in the United States and the Netherlands, with two segments, RENB and RENC. Its work included genetically modified allogeneic dendritic cell vaccines: RENB-DC11 for solid tumors, mainly pancreatic, and RENB-DC20 for breast cancer.
It also built an AI platform that uses a multi-omics approach to look for biomarkers of early cancer and recurrence, even in patients without symptoms, and partnered with Nebul on early disease detection.
Formerly Renovaro Inc., it changed its name to Lunai Bioworks Inc. in August 2025 and was based in Los Angeles, California. Its stock was delisted from the Nasdaq in September 2025, with a final trade on September 29, 2025 at $1.27.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Los Angeles, CA
- Employees
- 25
- IPO date
- February 2, 2015
- Delisted
- September 29, 2025
- SEC CIK
- 1527728
Renovaro Biosciences financials before the delisting
The last 5 fiscal years Renovaro Biosciences reported as a public company, fiscal year ending June.
RENB revenue and net income
RENB earnings per share
RENB annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0.00 | −$80.7M | −$7.93 |
| FY2024 | $0.00 | −$80.7M | −$1.85 |
| FY2023 | $0.00 | −$39.7M | −$6.82 |
| FY2022 | $0.00 | −$113.4M | −$17.47 |
| FY2021 | $0.00 | −$26.7M | −$0.56 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Renovaro Biosciences stock FAQ
What happened to Renovaro Biosciences stock?
Renovaro Biosciences was delisted from the Nasdaq in September 2025. The final close was $1.27 on September 29, 2025.
Can I still buy RENB stock?
No. RENB is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on September 29, 2025.
What was the last price of RENB?
RENB last closed at $1.27 on September 29, 2025, which valued the company at about $29.35M.
How did Renovaro Biosciences do in its last full fiscal year?
In fiscal 2025, its last full year as a public company, Renovaro Biosciences reported revenue of $0.00 and net income of −$80.7M.
When did Renovaro Biosciences go public?
Renovaro Biosciences shares started trading on February 2, 2015.
RENB no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.